Teva Hears No Again In Risperdal Spat

Law360, New York (November 10, 2008, 12:00 AM EST) -- Shedding some light on its earlier decision, the U.S. District Court for the District of Columbia has reiterated its decision to deny Teva Pharmaceuticals Inc.'s ongoing bid for marketing exclusivity for a generic version of anti-psychotic drug Risperdal.

On Monday, the D.C. Circuit issued a written opinion in Teva's dispute with the U.S. Food and Drug Administration over Risperdal, explaining why it had sided with the agency in an expedited mandate in September.

“Teva’s abbreviated new drug application did not meet the clear and unambiguous requirements...
To view the full article, register now.